Global Cord Blood Co. (NYSE:CO - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.03 and traded as high as $1.26. Global Cord Blood shares last traded at $1.19, with a volume of 42,087 shares.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen started coverage on Global Cord Blood in a research note on Saturday, May 17th. They issued a "strong-buy" rating for the company.
Get Our Latest Analysis on Global Cord Blood
Global Cord Blood Stock Performance
The company has a market capitalization of $144.04 million, a PE ratio of 1.85 and a beta of 0.16. The stock has a fifty day moving average of $0.98 and a 200 day moving average of $1.03.
About Global Cord Blood
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Stories
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
